Fresenius SE Cost of Goods Sold 2016-2024 | FSNUY
Fresenius SE annual/quarterly cost of goods sold history and growth rate from 2016 to 2024. Cost of goods sold can be defined as the difference between beginning and ending inventories for tangible products resulting in an expense that reflects production and sales costs.
- Fresenius SE cost of goods sold for the quarter ending June 30, 2024 was $4.563B, a 47.86% decline year-over-year.
- Fresenius SE cost of goods sold for the twelve months ending June 30, 2024 was $10.857B, a 67.01% decline year-over-year.
- Fresenius SE annual cost of goods sold for 2023 was $18.66B, a 41.19% decline from 2022.
- Fresenius SE annual cost of goods sold for 2022 was $31.729B, a 1.43% decline from 2021.
- Fresenius SE annual cost of goods sold for 2021 was $32.191B, a 8.55% increase from 2020.
Fresenius SE Annual Cost of Goods Sold
(Millions of US $) |
| 2023 |
$18,660 |
| 2022 |
$31,729 |
| 2021 |
$32,191 |
| 2020 |
$29,655 |
| 2019 |
$28,068 |
| 2018 |
$27,985 |
| 2017 |
$26,460 |
| 2016 |
$22,082 |
| 2015 |
$21,200 |
Fresenius SE Quarterly Cost of Goods Sold
(Millions of US $) |
| 2024-06-30 |
$4,563 |
| 2024-03-31 |
$4,666 |
| 2023-12-31 |
$-2,993 |
| 2023-09-30 |
$4,621 |
| 2023-06-30 |
$8,752 |
| 2023-03-31 |
$8,280 |
| 2022-12-31 |
$8,071 |
| 2022-09-30 |
$7,810 |
| 2022-06-30 |
$7,811 |
| 2022-03-31 |
$8,037 |
| 2021-12-31 |
$8,317 |
| 2021-09-30 |
$8,020 |
| 2021-06-30 |
$7,986 |
| 2021-03-31 |
$7,868 |
| 2020-12-31 |
$8,027 |
| 2020-09-30 |
$7,498 |
| 2020-06-30 |
$7,013 |
| 2020-03-31 |
$7,118 |
| 2019-12-31 |
$7,314 |
| 2019-09-30 |
$6,978 |
| 2019-06-30 |
$6,972 |
| 2019-03-31 |
$6,805 |
| 2018-12-31 |
$7,099 |
| 2018-09-30 |
$6,741 |
| 2018-06-30 |
$7,036 |
| 2018-03-31 |
$7,108 |
| 2017-12-31 |
$7,116 |
| 2017-09-30 |
$6,824 |
| 2017-06-30 |
$6,480 |
| 2017-03-31 |
$6,041 |
| 2016-12-31 |
$5,726 |
| 2016-09-30 |
$5,567 |
| 2016-06-30 |
$5,524 |
| 2016-03-31 |
$5,266 |
| 2015-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$20.419B |
$24.011B |
|
Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany.
|
